Vial
@VialTrials
Followers
678
Following
5
Media
10
Statuses
11
Next-generation pharma company. Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need.
San Francisco, CA
Joined April 2022
Dr. Deepak (@P_DeepakIBDMD), Director of Clinical and Translational Research in Gastroenterology at WashU, notes that an extended half-life anti-TL1A therapeutic will be very welcome to patients. Learn more about Vial’s half-life extended anti-TL1A:
0
1
5
Dr. Caroline Hwang, Program Director for the Margolis Family IBD Program at Hoag, discusses daily patient challenges and how an extended half-life therapeutic could significantly help. Learn more about Vial’s half-life extended anti-TL1A:
0
0
2
Dr. Jean-Frederic Colombel (@JeanFredericCo1), Director of the IBD Clinical Center at the Icahn School of Medicine at Mount Sinai, believes that the key for new IBD treatments could be convenience. Learn more about Vial’s half-life extended anti-TL1A:
0
0
3
Vial is advancing an innovative portfolio of wholly-owned biologics and RNAi therapies. Explore the transformative science defining our next-generation pipeline below.
0
0
1
Dr. Bincy Abraham (@IBD_Houston), Professor of Clinical Medicine at Houston Methodist, offers insights into the benefits of once-yearly dosing for IBD patients. Learn more about Vial’s half-life extended anti-TL1A:
0
1
9
Dr. Viral Patel, a Gastroenterologist at Charlotte Gastroenterology, highlights how an extended half-life TL1A therapeutic could make long-term IBD management significantly easier for patients. Learn more about Vial’s half-life extended anti-TL1A:
0
0
1
Dr. Silvio Danese, Professor of Gastroenterology at USR, offers insights into the potential of an extended half-life TL1A therapeutic, emphasizing its value for patient care and clinical practice. Learn more about Vial’s half-life extended anti-TL1A:
0
0
1
What if IBD treatment could feel less like a burden? Dr. Peter Higgins shares powerful insight on how reducing treatment frequency could dramatically improve the patient experience.
0
0
2
Vial begins dosing first participants with its anti-TL1A mAb. Engineered with proprietary half-life extension, it aims for best-in-class dosing interval for improved patient convenience and efficacy. Check out our press release:
0
0
1
Our first participant is dosed with Vial’s HLE anti-TL1A antibody, a potential best-in-class therapeutic for Inflammatory Bowel Disease. The Vial team is proud to mark this milestone as we continue advancing new options for patients with inflammatory disease.
0
0
1
Our first participant has been successfully dosed in the Phase 1 healthy volunteer trial of Vial’s half-life extended anti-TL1A antibody. Read the full press release:
0
0
3